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Conclusions: VinV –TAVI is widely performed, albeit in small numbers, in majority of
centers in the Nordic countries. The short-term results are excellent on this high-risk
patient population, demonstrating a low incidence of procedure-related complications.
However, a number of patients are left with suboptimal systolic valve performance with
unknown long-term effects, warranting a close surveillance after VinV-TAVI.
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Background: The last few years, transcatheter aortic valve implantation (TAVI) has
evolved as a good alternative treatment for patients rejected or with high risk for aortic
valve replacement (AVR). Very few studies report reasons for rejection for TAVI and the
outcome of these rejected patients. The purpose of this study is to investigate the reasons
for rejection for TAVI and compare survival between rejected and treated patients.
Methods: In this retrospective single center study patients referred for TAVI between
October 2007 and September 2011 are included. Reasons for rejection for TAVI were
collected and survival was compared for conservative treatment with transfemoral or
transapical TAVI and surgical AVR.
Results: We included 374 patients(mean age 81 years, 49% male); 150 patients were
rejected for TAVI. Reasons for rejection were: multiple comorbidities (24%), surgical
candidate (14%), other heart disorders (poor left ventricular function and/or other valve
abnormalities) (10%), asymptomatic or no severe aortic stenosis (7%), poor renal
function, malignancy, severely impaired lung function, cognitive reasons, poor peripheral
vessels and extreme high age. A total of 160 patients were treated by transfemoral TAVI
and 64 patients by transapical TAVI. Patients treated by TAVI or surgically had a
significant better 2-year survival than patients treated conservatively.
Conclusions: There are many reasons for rejection for TAVI, but the main reason was
multiple comorbidities. Patients with symptomatic severe aortic valve stenosis treated by
TAVI or surgical have a better survival than patients treated conservative.
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Background: Severe aortic regurgitation (AR), when intervention is required, is
managed by surgical aortic valve replacement (SAVR). TAVR could be a valid “off label”
option to treat severe AR for patients unsuitable for SAVR due to their high surgical risk.
However, in severe AR, large aortic annulus and poor aortic valve calcifications made
challenging TAVR. We hereby report our single centre experience of 8 cases (see Table)
of AR in which surgical correction was excluded because of high predicted operative
mortality. These cases were treated with TAVR using Medtronic CoreValve prostesis.
Total of patients 8
Age y (mean) 81
NYHA class III-IV pre TAVR % I00
L-Euroscore % 31
2 valve requirement (valve-in-valve) 0%
Ao regurgitation post TAVR  2 20%
New permanent PM implantation % 40
6 month mortality none
Methods: In all cases an oversizing prosthesis was used. Pre-dilation with balloon
valvuloplasty was never performed. During valve deployment a rapid (180 bpm) pacing
was used in order to prevent valve ejection.
Results: In our patients there were no peri-procedural major complications (stroke, major
bleeding). A new permanent PM implantation was necessary in 3 pts. At the 30-days and
6-month follow up we observed an improved functional capacity and no death.
Conclusions: TAVR in AR remains an off-label application needing further study.
However in selected cases may be considered as a valid option to treat severe AR in
patients unsuitable for SAVR.
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Background: TAVR has become a standard therapy for patients with severe aortic
stenosis considered to be inoperable or at very high risk for surgery. For both types of
currently available prostheses (the selfexpanding CoreValve (Medtronic, Minneapolis,
MN) and the ballon-expandable Edwards–Sapien XT (Edwards Lifesciences, Irvine, CA))
the standard procedure includes a balloon predilation as part of the procedure before
implanting the actual device. Although predilation of the calcified valve may facilitate
device placement, it bears a risk of stroke and conduction disturbances, two major
drawbacks of this procedure.
Methods: We performed a prospective study in 74 consecutive patients to investigate the
feasibility and procedural results of direct implantation of the selfexpanding Medtronic
CoreValve prosthesis without predilation.
Results: A total of 74 consecutive patients implanted with a CoreValve aortic biopros-
thesis were included in our study. Successful implantation was achieved in 73 (98.6%) of
the patients. Postdilation was necessary in 27% of the cases. Evaluation of outcome after
30 days showed a stroke/TIA rate of 2.7% with a 1.3% rate of major stroke. At 30 days
need for permanent pacemaker insertion post TAVR was 21.7% and overall mortality was
4.1 %. Procedural results showed an average implantation depth of 5.93.2 mm below
the annulus line and a rate of postprocedural aortic regurgitation  grade 2 of 1.4%.
Conclusions: Direct implantation of the CoreValve selfexpanding aortic bioprosthesis
without predilation is feasible and may be a safe alternative to the standard procedure
using predilation. Procedural results showed a low number of strokes and need for
postinterventional pacemaker implantation. Prospective studies should be performed to
compare both techniques of implantation with respect to periprocedural stroke rates and
need for pacemaker implantation.
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Background: Elevated concentrations of troponin T (cTnT) have prognostic impact in
patients with aortic stenosis. For patients with high risk for conventional aortic valve
replacement, transcatheter aortic valve replacement (TAVR) has become an established
therapeutic option.
Methods: We conducted a retrospective analysis in 201 consecutive patients scheduled
for transfemoral TAVR and analyzed predictors, kinetics and prognostic values of pre-
and postinterventional troponin T levels by using a high sensitive troponin T assay (Roche
Diagnostics).
Results: Patients with severe aortic stenosis had significantly elevated levels of cTnT
detectable before TAVR. Postinterventional cTnT levels rose significantly about seven
fold after transfemoral TAVR. Cardiac cTnT levels were highest at day 3 after TAVR
(204 11 pg/ml (mean SEM) compared to 43 3.1 pg/ml before TAVR) and steadily
declined thereafter. Baseline renal function (p0.011), the duration of intraprocedural
rapid pacing (P0.0012) left ventricular mass (p0.01) and baseline cTnT (p0.0001)
values were related to postinterventional cTnT release. Interestingly, Kaplan-Meier
survival curve analysis revealed, that although cTnT levels were not predictive for
shortterm mortality, preinterventional as well as postinterventional peak cTnT showed
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prognostic value for 1-year mortality independently of successful TAVR (p0.024 and
p0.012 respectively).
Conclusions: Thus pre- and postinterventional hscTnT levels demonstrate preserved
longterm prognostic value in patients with severe aortic stenosis and may reflect a
mortality risk independently of successful TAVR.
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Background: Chronic obstructive pulmonary disease (COPD) has been associated with
higher mortality following transcatheter aortic valve implantation (TAVI), but no data
exist on the factors determining poorer outcomes and functional status improvement in
these patients.
Methods: A total of 210 consecutive patients (29.5% COPD) who underwent TAVI were
studied. Baseline, procedural characteristics and follow-up (median of 12 [6-24] months)
data were prospectively collected. Functional status, as evaluated by NYHA class, Duke
Activity Status Index (DASI) and 6-minute walking test (6MWT), were performed at
baseline and at 6-12 months.
Results: COPD patients were younger, more frequently male and had a history of
smoking, peripheral vascular disease and diabetes mellitus. Survival rates at 1 year after
TAVI were 66% in COPD versus 85% in no-COPD patients (p0.002). In multivariate
analysis, COPD was an independent predictor of cumulative mortality following TAVI
[HR: 2.49, 95% CI: 1.38-4.48, p0.003]. Among COPD patients, a shorter distance in the
pre-procedure 6MWT predicted cumulative mortality [HR: 1.25 for each decrease of
20 m, 95% CI: 1.05-1.49, p0.014], whereas poorer baseline spirometry results (FEV1)
determined a higher rate of periprocedural pulmonary complications [OR: 1.44 for each
decrease of 5%, 95% CI: 1.03-2.0, p0.031]. Baseline FEV1 60% of predicted and a
distance 150 m in the 6MWT best determined the occurrence of periprocedural
pulmonary complications and midterm mortality, respectively. A significant improvement
in functional status was observed following TAVI (p0.001 for changes in NYHA class,
DASI and 6MWT), without differences in the degree of functional improvement between
COPD and no-COPD patients (pNS between groups for changes in NYHA, DASI and
6MWT).
Conclusions: COPD was associated with a higher rate of mortality at midterm follow-up.
Among COPD patients, a higher degree of airway obstruction and a lower exercise
capacity determined a higher risk for pulmonary complications and mortality, respec-
tively. In addition, COPD patients who survived after TAVI exhibited similar improve-
ments in functional status as the rest of the study population.
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Background: Normal aortic and mitral valves function in a reciprocal interdependent
fashion. We hypothesized that the mitral valve function would be affected by severe aortic
stenosis (AS) and that its function would remain altered after transcatheter aortic valve
implantation (TAVI). Using three-dimensional (3D) echocardiography, we studied
aortic-mitral coupling in AS patients undergoing TAVI and compared them to patients
without AS.
Methods: 3D transesophageal echocardiography (Philips) was performed on 38 patients:
16 controls and 22 with severe AS, studied pre- and post-TAVI. Custom software tracked
the aortic and mitral annuli (AA, MA), allowing automated measurements of AA and MA
morphology, angle and motion throughout the cardiac cycle.
Results: Compared to controls, pre-TAVI patients had significantly reduced MA
displacement, MA and AA areas (Table). Post-TAVI, MA displacement, MA and AA
areas remained reduced. AA-MA angle was significantly wider at end-systole in
pre-TAVI patients and became wider throughout the cardiac cycle post-TAVI. There was
no difference in MA or AA dynamics between pre-TAVI patients with mild versus those
with moderate-severe MA calcium, or between Edwards-Sapien and Medtronic Cor-





Maximum AoA area (during
systole), cm sq.
5.3	1.1 4.5	1.1 3.3	0.6#




Maximum MA area (during
diastole), cm sq
10.7	2.1 8.5	2.0 8.1	1.9









MA longitudinal displacement, mm 7.8	3.2 5.4	2.3 5.8	2.1
Aortic-mitral annular angle
Maximum Ao-MA angle, degree 122	19 129	20 136	19
Minimum Ao-MA angle, degree 98	16 113	17* 119	20
data presented as mean	sd; p0.05 compared to Controls; †p0.1 compared to
Controls; #p0.05 compared to Pre-TAVI
Conclusions: This study is the first to demonstrate that the effect of severe degenerative
AS extends to a secondary, ‘unaffected’ valve, the mitral valve, due to calcification in the
aortic-mitral fibrous continuity. TAVI does not result in recovery of mitral valve function
as the prosthetic ring compresses the calcified aortic valve into the aortic-mitral fibrous
continuity. These changes not only provide insight into a possible mechanism for
prosthetic aortic valve failure, but also have implications in the future development of
TAVI valves and possible need for mitral valve assessment before and after the procedure.
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Background: Prosthesis patient mismatch (PPM) is an independent predictor of
mortality post aortic valve replacement. We sought to determine if 3-dimensional aortic
annular measurements by multi-detector computed tomography (MDCT) are predictive of
PPM post transcatheter aortic valve replacement (TAVR).
Methods: 128 patients underwent MDCT then TAVR. Moderate PPM was defined as an
indexed effective orifice area 0.85 cm2/m2 and severe 0.65 cm2/m2. MDCT annular
measurements (area, short and long axis) were compared with the size of the selected
transcatheter heart valve (THV) to obtain a) the difference between prosthesis size and CT
measured mean annular diameter, and b) the percentage of undersizing (calculated as 100
* (MDCT annular area  THV nominal area)/ THV nominal area). Additionally, the
MDCT annular area was indexed to body surface area. These measures were evaluated as
potential predictors of PPM.
Results: On discharge echocardiography, 42.2% (54/128) had moderate PPM and 9.4%
(12/128) severe PPM. Procedural characteristics and in-hospital outcomes did not differ
between those with or without PPM. THV undersizing of the mean diameter was not
predictive of moderate (OR 0.84, 95% CI 0.65 – 1.07, p0.16, AUC 0.58) or severe PPM
(OR 0.84, 95% CI 0.55-2.1, p 0.79, AUC 0.59). THV undersizing of annular area was
not predictive of moderate (OR 0.96, 95% CI 0.80-1.16, p0.69, AUC 0.52) or severe
PPM (OR 0.95, 95% CI 0.70-1.30, p0.74, AUC 0.53). Indexed MDCT annular area was
predictive of PPM (OR 0.24, 95% CI 0.10 – 0.59, p  0.001, AUC 0.66).
Conclusions: Severe PPM is not infrequent post TAVR. The etiology of PPM is not
related to undersing of the THV relative to 3-D aortic annular size by MDCT. Indexed
MDCT annular area is moderately predictive of PPM.
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AM www.jacc.tctabstracts2012.com
B248 JACC Vol 60/17/Suppl B | October 22–26, 2012 | TCT Abstracts/POSTER/Aortic Valve Disease and TAVR
P
O
ST
E
R
S
